Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Holdings Lifted by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 464,003 shares of the specialty pharmaceutical company's stock after purchasing an additional 97,589 shares during the period. GW&K Investment Management LLC owned about 0.77% of Jazz Pharmaceuticals worth $57,142,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $25,000. UMB Bank n.a. boosted its stake in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. Itau Unibanco Holding S.A. increased its position in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock worth $49,000 after purchasing an additional 172 shares in the last quarter. GAMMA Investing LLC raised its stake in Jazz Pharmaceuticals by 49.8% in the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company's stock valued at $76,000 after purchasing an additional 206 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after purchasing an additional 704 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded down $1.27 during midday trading on Tuesday, hitting $138.95. 877,538 shares of the stock traded hands, compared to its average volume of 727,900. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The business's 50 day moving average price is $127.01 and its two-hundred day moving average price is $119.37. The firm has a market capitalization of $8.44 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on JAZZ shares. Royal Bank of Canada lowered their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC raised their price target on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $182.47.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the completion of the transaction, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,113 shares of company stock valued at $2,551,834 in the last ninety days. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.